AbbVie has agreed to spend $1.4 billion to purchase Aliada Therapeutics. Through...
Izervay by Astellas and Syfovre by Apellis are the major rivals in the United St...
Apellis Pharmaceuticals and Novartis recently shared data for their rare kidney ...
With the formation of a new strategic partnership, Dyno Therapeutics is responsi...
Bladder cancer is the ninth most common cancer globally, and the number of diagn...
Biogen and Neomorph have partnered to discover and develop molecular glue degrad...
Pharmaceutical management expert Kenneth Getz shares insights on broader trends ...
Amidst a share value slump and executive turmoil, Pfizer reported a robust quart...
The company has axed 80% of its staff and is considering a wind-down after the o...
As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its ...
Reeves' budget promised investment for innovation and R&D with a view to "harnes...
Experts predict that physicians may favour emerging biosimilar versions of Stela...
AbbVie has entered a definitive agreement to acquire all outstanding equity of A...
As the retail drug pharmacy space undergoes significant change, new formats and ...
UPFs have become a staple of many diets worldwide, but overconsumption is contri...
